Status:
COMPLETED
A 6-Months Infliximab Or Placebo Study In UA At High Risk Of RA:Clinical,Radiological And Synovial Benefit
Lead Sponsor:
Patrick Durez
Conditions:
Undifferentiated Arthritis
Eligibility:
All Genders
Phase:
NA
Brief Summary
Patient with undifferentiated arthritis and the presence of anti-citruline (anti-CCP) antibodies are at high risk to develop RA. The presence of anti-CCP is associated with a higher rate of erosion an...
Detailed Description
not necessary
Eligibility Criteria
Inclusion
- Diagnosis of UA Absence of American College of Rheumatology (ACR) criteria Active UA defined by a swollen joint count ≥ 1 and \< 4 Positive anti-CCP Disease duration \< 2 years DMARDs naive No chronic treatment with steroids (\> 3 months), if needed washout of 4 weeks NSAIDs stable
Exclusion
- Other rheumatic inflammatory diagnosis Contraindication to MRI (pace-maker, etc.) Congestive heart disease Active or latent tuberculosis
Key Trial Info
Start Date :
November 1 2007
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
December 1 2012
Estimated Enrollment :
30 Patients enrolled
Trial Details
Trial ID
NCT01245361
Start Date
November 1 2007
End Date
December 1 2012
Last Update
October 31 2013
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Université Catholique de Louvain
Brussels, Belgium, 1200